ESPR
- Esperion Therapeutics, Inc.
()
Overview
Company Summary
Esperion Therapeutics, Inc. (ESPR) is a biopharmaceutical company that focuses on developing and commercializing novel therapies for the treatment of cardiovascular diseases. Specifically, the company is dedicated to addressing the unmet medical needs of patients with high cholesterol levels and other risk factors for heart diseases.
Esperion Therapeutics primarily focuses on developing drugs that target LDL cholesterol, commonly known as "bad" cholesterol. Elevated LDL levels are a significant risk factor for developing cardiovascular diseases such as atherosclerosis, heart attack, and stroke. The company's research and development efforts aim to discover and develop innovative therapies that can effectively lower LDL cholesterol levels in patients.
Their flagship product is bempedoic acid, an oral, once-daily medication designed to lower LDL cholesterol. Bempedoic acid works by blocking an enzyme involved in cholesterol synthesis, thus reducing the production of LDL cholesterol in the liver. This drug is intended to be used in combination with other lipid-lowering therapies, such as statins, to further enhance cholesterol reduction.
In addition to bempedoic acid, Esperion Therapeutics is also developing other pipeline candidates targeting cholesterol management. This includes combination therapies and potential treatments for a range of lipid disorders. The company's research and development efforts focus on discovering alternative treatment options that may offer benefits to patients who cannot tolerate or do not appropriately respond to existing therapies.
Esperion Therapeutics, Inc. aims to provide physicians and patients with effective and safe therapies that can address the growing burden of cardiovascular diseases, particularly related to elevated LDL cholesterol levels. Through their research, development, and commercialization activities, ESPR works towards improving patients' lives and contributing to the advancement of cardiovascular care.